{"id":14568,"date":"2017-06-20T11:10:54","date_gmt":"2017-06-20T11:10:54","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=14568"},"modified":"2019-01-11T07:35:09","modified_gmt":"2019-01-11T07:35:09","slug":"restoration-of-physiological-activity-of-platelets-in-new-born-calves-with-iron-deficiency","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol10no2\/restoration-of-physiological-activity-of-platelets-in-new-born-calves-with-iron-deficiency\/","title":{"rendered":"Restoration of Physiological Activity of Platelets in New-Born Calves With Iron Deficiency"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

It becomes clear that \u00a0the phase of cattle new-born state is a very important development stage\u00a0 for the whole subsequent ontogenesis.1,2<\/sup> Well-being and ill-being of environmental conditions at this life stage can seriously influence subsequent phases of early ontogenesis including realization processes of\u00a0 hereditary information during growth, development and reproduction.3,4<\/sup> At the same time, at many Russian farms new-born calves are often found to have different abnormalities negatively influencing their metabolism processes and finally \u2013 their growth and development.5<\/sup> In previous researches it was found that at homeostasis deviations especially in case of a young organism there can happen quick increase of hemostasis components\u2019 activity able to lead to microcirculation disturbance.6,7<\/sup> The most numerous researches in this field were made with human beings.8,9,10<\/sup> Being based on their results we managed to make a conception of\u00a0 the presence of age-specific dynamics of hemostasis components\u2019 activity,11,12<\/sup> most vulnerable its mechanisms and the potential of different influencing varients on the organism aiming at hemostatic processes optimization. Because of great social significance of thrombosis at cardial pathology13,14<\/sup> modern researchers firmly retain their attention at the aspects of hemostatic changes appearing at the given category of patients.15,16,17<\/sup> Exactly while studying hemostasiopathy pathogenesis at cardial pathology there was formulated the understanding of\u00a0 its correction possibility not only with the help of usual cardiological means18,19,20<\/sup> but there was shown their minimization possibility with the help of\u00a0 traditional applications21,22,23\u00a0<\/sup>what is really important for biological researches.<\/p>\n

As the state of iron deficit is spread enough among new-born calves1,5<\/sup> and it is rather often accompanied by development of disturbances in hemostasis system24<\/sup> there is a great practical demand in their quick and effective removal among calves at farms. At the same time effective approaches aimed at simultaneous reduction of iron deficit and hemostasiopathy signs are still worked out unsatisfactorily.25<\/sup><\/p>\n

That\u2019s why investigations led with new-born calves with the aim of finding approaches to early and effective hemostasiopathy correction on the model of iron deficit state keep their great scientific and practical significance. Worked out at the given state varients of evidence decrease of hemostasis disturbances can serve the basis for the following creation of\u00a0 correction complexes able to be effective in the field of hemostasiopathy reduction of new-born calves at many diseases. Great interest should exist to the evaluation of influence\u00a0 on the whole hemostasis system of the combination of traditionally applied at iron deficit ferroglukin25<\/sup> and earlier shown their high biological activity and ability to influence hemostasis system separate components metabolically active means \u2013 polyson26<\/sup> and cresacin.27<\/sup><\/p>\n

In this connection we put the following aim for our investigation \u2013 to find the evidence of platelets activity correction of new-born calves with iron deficit with the help of ferroglukin, polyson and cresacin combination.<\/p>\n

Materials and Methods<\/strong><\/p>\n

The work was fulfilled with 37 new-born calves having the signs of\u00a0 erythrogenesis and decrease of iron content in their organisms (serum iron 13,1\u00b10,09mkmol\/l, siderocytes 1,5\u00b10,05%, haemoglobin 98,2\u00b10,25g\/l, erythrocytes 4,2\u00b10,18×1012<\/sup>\/l). The control group contained 29 healthy new-born calves.<\/p>\n

The state of lipids\u2019 peroxidation (LPO) in animals\u2019 plasma was found out according to the quantity in it of thiobarbituric acid \u2013 active products with the help of a set by the firm \u201cAgat-Med\u201d (Russia) and acylhydroperoxides with the account of antioxidant activity level of the liquid part of blood.28<\/sup> Thrombocytes\u2019 number in calves\u2019 blood was found out by their calculation in Gorjaev\u2019s chamber. Thrombocytes aggregation was registered\u00a0 by visual micromethod29<\/sup> with some inductors: with ADP (0,5×10-4 <\/sup>M), with thrombin\u00a0 (0,125un\/ml), with collagen (dilution 1:2 of the main suspension), with rhystomicin (0,8 mg\/ml), with adrenalin\u00a0 (5×10-6<\/sup> M) in plasma with standardized quantity of thrombocytes in it \u00a0(200×109<\/sup> tr.).<\/p>\n

The correction of iron deficit state of new-born calves was realized by ferroglukin intramuscularly, once from the calculation of 15mg of iron on 1kg of body mass, polyson 5mg\/kg in the morning in the scheme of liquid feeding during 6 days and cresacin \u2013 every day 3mg\/kg in the scheme of liquid feeding during 6 days beginning simultaneously with ferroglukin application. Evaluation of healthy animals\u2019 state was made two times \u2013 at their birth and on the 7th<\/sup> day of life. Because of the absence of reliable differences between the results of both investigations control values of each index are presented by one figure \u2013 a simple average between them. Examination of calves having iron deficit was fulfilled twice \u2013 at their birth and on the next day after correction finish (the 7th<\/sup> day of life). Statistical processing of received data was fulfilled by Student\u2019s t-criteria.<\/p>\n

Results<\/strong><\/p>\n

Examined new-born calves with iron deficit were found to have characteristic for the given state weakness, limpness, absence of interest to the environment, paleness of rhinoscope and slime layers. These animals were noted to have increased LPO activity in plasma (acylhydroperoxide 3,41\u00b10,022 D233<\/sub>\/1ml, thiobarbituric acid- active products 5,20\u00b10,027 mkmol\/l \u00a0at value depression of blood liquid part antioxidant activity 22,2\u00b10,15%). The values of these indices under control were equal to 1,45\u00b10,010 D233<\/sub>\/1 ml, 3,46\u00b10,012 mkmol\/l and 33,7\u00b10,15% correspondingly.<\/p>\n

Thrombocytes\u2019 quantity in new-born calves\u2019 blood corresponded to norms. Besides, thrombocytes\u2019 aggregation of animals with iron deficit turned out to be reliably increased (table). Their earliest thrombocytes\u2019 aggregation appeared in response to collagen\u00a0 (19,2\u00b10,21s), a bit later it developed with ADP and with rhystomicin, still later in response to thrombin (36,5\u00b10,12s). The latest thrombocytes\u2019 aggregation of calves with iron deficit appeared under adrenalin influence (67,9\u00b10,23s).<\/p>\n

Table 1: Parameters of hemostasis in newborn calves with<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Consider indicators<\/strong><\/td>\nCalves with iron deficiency, n=37, M\u00b1m<\/strong><\/td>\ncontrol,<\/strong><\/td>\noutcome<\/strong><\/td>\nafter the correction<\/strong><\/td>\nn=29, M\u00b1m<\/strong><\/td>\n<\/tr>\n
platelet aggregation with ADP, s<\/td>\n26,0\u00b10,16<\/td>\n40,1\u00b10,12<\/td>\n40,2\u00b10,08<\/td>\n\u04401<\/sub><0,01<\/td>\n\u0440<0,01<\/td>\n<\/tr>\n
platelet aggregation with collagen, s<\/td>\n19,2\u00b10,21<\/td>\n31,3\u00b10,08<\/td>\n31,4\u00b10,08<\/td>\n\u04401<\/sub><0,01<\/td>\n\u0440<0,01<\/td>\n<\/tr>\n
platelet aggregation with thrombin, s<\/td>\n36,5\u00b10,12<\/td>\n54,2\u00b10,20<\/td>\n53,8\u00b10,07<\/td>\n\u04401<\/sub><0,01<\/td>\n\u0440<0,01<\/td>\n<\/tr>\n
platelet aggregation with rystomicin, s<\/td>\n21,0\u00b10,19<\/td>\n48,1\u00b10,14<\/td>\n48,0\u00b10,12<\/td>\n\u04401<\/sub><0,01<\/td>\n\u0440<0,01<\/td>\n<\/tr>\n
platelet aggregation with adrenalin, s<\/td>\n67,9\u00b10,23<\/td>\n97,4\u00b10,16<\/td>\n97,6\u00b10,06<\/td>\n\u04401<\/sub><0,01<\/td>\n\u0440<0,01<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Legend: \u00a0p – reliability of differences of indicators between the control and the initial state of the calves with iron deficiency, p1<\/sub> \u2013 reliability of dynamics of indicators in calves with iron deficiency against the background of correction.<\/p>\n

Realized state correction provided examined calves with iron deficit improvement of the common state and their activity, increase of their serum iron level to the control values (23,2\u00b10,21 mkmol\/l). On the background of ferroglukin, polyson and cresacin combination examined calves were found to have evident plasma content decrease of\u00a0 acylhydroperoxides (1,70\u00b10,014 D233<\/sub>\/1 ml, p<0,05) and thiobarbituric acid-active products (3,87\u00b10,019 mkmol\/l, p<0,05) at the increase of antioxidant activity to 28,6\u00b10,16% (p<0,05).<\/p>\n

Correction realization of animals having at the beginning iron deficit was accompanied by invariability of\u00a0 thrombocytes\u2019 quantity in their blood and slowdown of thrombocytes\u2019 aggregation to the control level. Besides, most actively animals\u2019 thrombocytes responded by aggregation to collagen, ADF and rhystomicin, less actively \u2013 to thrombin and adrenalin addition into plasma (table).<\/p>\n

Discussion<\/strong><\/p>\n

Realization of genetically defined growth and development processes of living organisms takes place at constant influence on organism of numerous factors of environment and internal environment.4,30<\/sup> Physiological peculiarities of their influence are mostly expressed by the optimum of living beings\u2019 blood content31,32<\/sup> especially as far as hemostasis system components\u2019 activity is concerned.33,34<\/sup> Besides, any disturbances in an organism are accompanied by negative dynamics of hematological indices9,35<\/sup> including parameters of hemostasis system.34,36<\/sup> It becomes clear, that in the basis of hemostasiopathy development in case of examined new-born calves we have not only iron deficit but also found during investigation depression of plasma antioxidant defence which as previous works showed causes LPO activation in it. Increase of peroxidation in plasma damages structures of blood platelets and vessels and affects their functions.37,38<\/sup> Found in new-born calves with iron deficit thrombocytes\u2019 aggregation acceleration points at the increase of their receptors\u2019 sensibility to stimulating influences from the outside.39<\/sup> Besides, active development of thrombocytes\u2019 aggregation in response to rhystomicin in case of calves with iron deficit should be regarded as consequence of their sensibility increase to Willybrand\u2019s factor.10<\/sup> Besides, acceleration of thrombocytes\u2019 aggregation coming\u00a0 of these animals indirectly tells about the increase in their blood platelets of exchange processes of arachidonic acid with surplus thromboxan A2<\/sub> formation.40<\/sup><\/p>\n

Application of ferroglukin, polyson and cresacin combination made new-born calves with iron deficit state feel saturation of their organisms with iron, positive dynamics of red blood and common animals\u2019 state indices. Fulfilled impact on examined calves\u2019 organisms was accompanied by lowering of their LPO processes intensity in plasma what weakened its damaging influence on endothelium and liver thrombocytes. Found normalization of thrombocytes aggregation of calves with iron deficit state after getting of ferroglukin, polyson and cresacin combination is mostly the consequence of these means combination positive impact on innerthrombocyte LPO, receptor and postreceptor thrombocytes\u2019 functioning mechanisms.10<\/sup> Developing in these conditions time increase of thrombocytes aggregation coming in response to rhystomicin pointed at lowering in these calves\u2019 blood of adhesion cofactor \u2013 Willybrand\u2019s factor.20<\/sup><\/p>\n

Conclusion<\/strong><\/p>\n

New-born calves having iron deficit are characterized by lowering of blood plasma antioxidant defence, intensification in it of LPO processes, increase of thrombocyte hemostatic activity. With the help of application to new-born calves with iron deficit of the combination of ferroglukin, polyson and cresacin we can really strengen plasma antioxidant defence, weaken LPO activity in it, normalize thrombocyte activity.<\/p>\n

Acknowledgements<\/strong><\/p>\n

The author thanks the Kursk Institute of Social Education (branch) of the Russian State Social University and the All-Russian Research Institute of Physiology, Biochemistry and Nutrition of Animals, Institute of Village for providing laboratory equipment and reagents.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

No conflict of interest to declare.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Yavuz E., Todorov N., Ganchev G and Nedelkov K. The effect of feeding different milk programs on dairy calf growth, health and development. Bulgarian Journal of Agricultural. Science.<\/em>\u00a02015;21:384-93.<\/li>\n
  2. Kutafina N. V and Medvedev I. N. Dynamics of physiological indicators of calves in early ontogenesis.\u00a0 Zootehniya.<\/em> 2015;3:25-7.<\/li>\n
  3. Amelina I. V and Medvedev I. N. Transcriptional activity of chromosome nucleolar organizing regions in population of Kursk region. Bulletin of Experimental Biology and Medicine.\u00a0<\/em>2009; 147(6):730-32.
    \nCrossRef<\/a><\/li>\n
  4. Amelina I. V and Medvedev I. N. Evaluation of the dependence of mutagenesis intensity on activity of nucleolus organizer regions of chromosomes in aboriginal population of Kursk region. Bulletin of Experimental Biology and Medicine.\u00a0<\/em>2008;145(1):68-71.
    \n    CrossRef<\/a><\/li>\n
  5. Belova \u0422. \u0410 and Medvedev I. N. Ontogenetic dynamics microrheological properties of red blood cells and platelets in calves of different physiological status. Kursk. 2011;268.<\/li>\n
  6. Glagoleva T. I. Functional and biochemical features of the body and blood parameters in cattle in ontogenesis. Veterinary Medicine, Animal Science and Biotechnology.\u00a0<\/em>2015;3:53-66.<\/li>\n
  7. Medvedev I. N., Lapshina E. V and Yu S. Z. Activity of platelet hemostasis in children with spinal deformities. Bulletin of experimental biology and medicine.<\/em>\u00a02010;149(5):645-46.
    \n    CrossRef<\/a><\/li>\n
  8. Shitikova A. S. Thrombocytopathy congenital and acquired. St. Petersburg. 2008;320.<\/li>\n
  9. Simonenko V. B., Medvedev I. N.,\u00a0 Mezentseva N. I\u00a0 and\u00a0 Tolmachev V. V. The antiaggregation activity of the vascular wall in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina.<\/em>\u00a02007;85(7):28-30.<\/li>\n
  10. Simonenko V. B., Medvedev I. N and Tolmachev V. V. Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina.<\/em>\u00a02007;85(4):24.<\/li>\n
  11. Kutafina N. V and Medvedev I. N. Platelet Aggregation in Clinically Healthy Persons of the Second Coming-of-Age Living in the Kursk Oblast. Advances in Gerontology.\u00a0<\/em>2015;5(4):267-70.
    \n    CrossRef<\/a><\/li>\n
  12. Medvedev I. N and Gromnatskii N. I. Correction of thrombocyte hemostasis and biological age reduction in metabolic syndrome. Klinicheskaia meditsina.<\/em>\u00a02005;83(8):54-7.<\/li>\n
  13. Simonenko V. B., Medvedev N and Kumova T. A. Pathogenetic aspects of hypertension in case of metabolic syndrome.\u00a0 Voenno-meditsinskii zhurnal.\u00a0<\/em>2010;331(9):41-4.<\/li>\n
  14. Simonenko V. B., Medvedev I. N and Tolmachev V. V. Pathogenetic aspects of arterial hypertension in\u00a0 metabolic syndrome. Klinicheskaia meditsina.\u00a0<\/em>2011;89(1):49-51.<\/li>\n
  15. Gromnatskii N. I and Medvedev I. N. Non-pharmacological correction of impaired platelet hemostasis in hypertensive patients with metabolic syndrome. Klinicheskaia meditsina.\u00a0<\/em>2003; 81(4):31-4.<\/li>\n
  16. Medvedev I. N., Gromnatskii N. I., Golikov B. M., Al’- Zuraiki E. M and Li V. I. Effects of lisinopril on platelet aggregation in patients with arterial hypertension with metabolic syndrome). Kardiologiia.<\/em> 2004;44(10):57-9.<\/li>\n
  17. Simonenko V. B., Medvedev I. N and Tolmachev V. V. Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan \/\/ Klinicheskaia meditsina. 2011;89(3):35-8.<\/li>\n
  18. Medvedev I. N and Gromnatskii N. I. Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome. Klinicheskaia meditsina.<\/em>\u00a02005;83(2):37-9.<\/li>\n
  19. Medvedev I. N and Gromnatskii N. I. The influence of nebivolol on thrombocyte aggregation in patients with arterial hypertension with metabolic syndrome. Klinicheskaia meditsina.\u00a0<\/em>2005; 83(3):31-3.<\/li>\n
  20. Medvedev I. N and Kumova T. A. Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome. Russian Journal of Cardiology.\u00a0<\/em>2008;1:40-2.<\/li>\n
  21. Medvedev I. N., Gromnatskii N. I., Volobuev I. V., Osipova V. M., Dement’ev V. I and Storozhenko M. V. Thrombocytic hemostasis in hypertensive patients with metabolic syndrome and its correction with lovastatin). Klinicheskaia meditsina.\u00a0<\/em>2004;82(10):37-41.<\/li>\n
  22. Medvedev I. N and Gromnatskii N. I. The influence of hypocaloric diet on thrombocyte rheology in patients with metabolic syndrome. Klinicheskaia meditsina.<\/em>\u00a02006;84(3):49-52.<\/li>\n
  23. Medvedev I. N and Savchenko A. P. Platelet activity correction by regular physical training in young people with high normal blood pressure. Russian Journal of Cardiology.\u00a0<\/em>2010;2(82):35-40.<\/li>\n
  24. Glagoleva T. I. The ability to aggregation of erythrocytes, platelets and white blood cells in the newborn calves. Veterinarian.<\/em>\u00a02015;3:49-53.<\/li>\n
  25. Glagoleva T. I.,Yu\u00a0S. Z and Medvedev I. N. Vascular control of platelet aggregation in the newborn calves with iron deficiency treated ferroglyukin. Modern high technologies.<\/em>\u00a02011;3:93.<\/li>\n
  26. Khusainov V. R and Fenchenko N. G.\u00a0 Polizon Impact on growth of pigs and the quality of their products. Siberian bulletin agricultural nauki.<\/em>\u00a02005;2:89-93.<\/li>\n
  27. Guryanov \u0410. \u041c., Petunenkov S. V., Borin A. V and Makarov I. I. The efficiency of feeding calves and feed additives Natuphos krezatcina composed of feed. Zootehniya.<\/em>\u00a02007;10:10-11.<\/li>\n
  28. Chevari S., Andyal T and Strenger J. Determination of antioxidant blood parameters and their diagnostic value in the elderly. Laboratory work. 1991;10:9-13.<\/li>\n
  29. Medvedev I. N., Savchenko A. P., Yu S. Z., Krasnova E. G. Kumova T. A., Gamolina O. V., Skoryatina I. A and Fadeeva T. S. Methodological approaches to the study of the rheological properties of blood in various states. Russian Journal of Cardiology.\u00a0<\/em>2009;5:42-5.<\/li>\n
  30. Medvedev I. N and Amelina I. V. An association between human morphological phenotypical characteristics and the activity of chromosomal nucleolar organizer regions in the interphase cell nucleus in the population of indigenous people of Kursk region. Morfology.<\/em>\u00a02012;142(4):87-91.<\/li>\n
  31. Medvedev I. N and Bryukhovetsky A. G. The use of verospiron and the degree of platelet aggregation in arterial hypertension with abdominal obesity. Klinicheskaia meditsina.\u00a0<\/em>2014:92(3): 50-53.<\/li>\n
  32. Medvedev I. N and Skoryatina I. A. Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin. Klinicheskaia meditsina.<\/em>\u00a02014;92(11):34-38.<\/li>\n
  33. Medvedev I. N and Skoryatina I. A. Pravastatin in correction of vessel wall antiplatelet control over the blood cells in patients with arterial hypertension and dyslipidemia. Cardiovascular therary and prevention.\u00a0<\/em>2014;13(6):18-22.<\/li>\n
  34. Medvedev I. N and Skoryatina I. A. Platelet hemostasis dynamics in simvastatin-treated patients with arterial hypertension and dyslipidemia. Russian Journal of Cardiology.\u00a0<\/em>2010;1(81):54-8.<\/li>\n
  35. Medvedev I. N and Skoriatina I. A. Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin. Klinicheskaia meditsina.\u00a0<\/em>2012;90(6):42-5.<\/li>\n
  36. Simonenko V. B., Medvedev I. N and Tolmachev V. V. Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome. Klinicheskaia meditsina.\u00a0<\/em>2010;88(6):27-30.<\/li>\n
  37. Medvedev I. N and Skoriatina I. A. Effect of lovastatin on adhesive and aggregation function of platelets in patients with arterial hypertension and dyslipidemia. Klinicheskaia meditsina.<\/em>\u00a02010;88(2):38-40.<\/li>\n
  38. Medvedev I. N and Skoryatina I. A. Fluvastatin effects on blood cell aggregation in patients with arterial hypertension and dyslipidemia. Cardiovascular Therapy and Prevention.<\/em>\u00a02013;12(2):18-24.
    \n    CrossRef<\/a><\/li>\n
  39. Burnier L., Fontana P.,\u00a0 Kwak B. R\u00a0 and Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Haemost.\u00a0<\/em>2009;101:439-51.
    \n    CrossRef<\/a><\/li>\n
  40. Simonenko V. B., Medvedev\u00a0 I. N and\u00a0 Gamolina O. V.\u00a0 Primary hemostasis activity in patients with arterial hypertension and impaired glucose tolerance treated with trandolapril. Klinicheskaia meditsina.\u00a0<\/em>2011;89(2):29-31.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction It becomes clear that \u00a0the phase of cattle new-born […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[49],"tags":[],"class_list":["post-14568","post","type-post","status-publish","format-standard","hentry","category-vol10no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/14568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=14568"}],"version-history":[{"count":16,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/14568\/revisions"}],"predecessor-version":[{"id":25519,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/14568\/revisions\/25519"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=14568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=14568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=14568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}